emeline maillet

Dr. emeline maillet


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
RMRobert F. Margolskee
Robert F. Margolskee
JDJane Dyer
Jane Dyer
ZKZaza Kokrashvili
Zaza Kokrashvili
KSKieron S. H. Salmon
Kieron S. H. Salmon
EIErwin Ilegems
Erwin Ilegems
SSSoraya P Shirazi-Beechey
Soraya P Shirazi-Beechey
Dietary sugars are transported from the intestinal lumen into absorptive enterocytes by the sodium-dependent glucose transporter isoform 1 (SGLT1). Regulation of this protein is important for the provision of glucose to the body and avoidance of intestinal malabsorption. Although expression of SGLT1 is regulated by luminal monosaccharides, the luminal glucose sensor mediating this process was unknown. Here, we show that the sweet taste receptor subunit T1R3 and the taste G protein gustducin, expressed in enteroendocrine cells, underlie intestinal sugar sensing and regulation of SGLT1 mRNA and protein. Dietary sugar and artificial sweeteners increased SGLT1 mRNA and protein expression, and glucose absorptive capacity in wild-type mice, but not in knockout mice lacking T1R3 or α-gustducin. Artificial sweeteners, acting on sweet taste receptors expressed on enteroendocrine GLUTag cells, stimulated secretion of gut hormones implicated in SGLT1 up-regulation. Gut-expressed taste signaling elements involved in regulating SGLT1 expression could provide novel therapeutic targets for modulating the gut's capacity to absorb sugars, with implications for the prevention and/or treatment of malabsorption syndromes and diet-related disorders including diabetes and obesity.

20 July 2010 in Science Signaling
Verified
Journal Article
Open access
PDF file
AGAchla Gupta
Achla Gupta
Jan MulderJan Mulder
Jan Mulder
IGIvone Gomes
Ivone Gomes
RRRaphael Rozenfeld
Raphael Rozenfeld
IBIttai Bushlin
Ittai Bushlin
LDLakshmi Devi
Lakshmi Devi
The μ-δ opioid heteromer may be a target for alleviation of chronic pain.

1 December 2006 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
MCMeng Cui
Meng Cui
PJPeihua Jiang
Peihua Jiang
EMemeline maillet
emeline maillet
MMMarianna Max
Marianna Max
RMRobert F. Margolskee
Robert F. Margolskee
RORoman Osman
Roman Osman
The sweet taste receptor is a heterodimer of two G protein coupled receptors, T1R2 and T1R3. This discovery has increased our understanding at the molecular level of the mechanisms underlying sweet taste. Previous experimental studies using sweet receptor chimeras and mutants show that there are at least three potential binding sites in this heterodimeric receptor. Receptor activity toward the artificial sweeteners aspartame and neotame depends on residues in the amino terminal domain of human T1R2. In contrast, receptor activity toward the sweetener cyclamate and the sweet taste inhibitor lactisole depends on residues within the transmembrane domain of human T1R3. Furthermore, receptor activity toward the sweet protein brazzein depends on the cysteine rich domain of human T1R3. Although crystal structures are not available for the sweet taste receptor, useful homology models can be developed based on appropriate templates. The amino terminal domain, cysteine rich domain and transmembrane helix domain of T1R2 and T1R3 have been modeled based on the crystal structures of metabotropic glutamate receptor type 1, tumor necrosis factor receptor, and bovine rhodopsin, respectively. We have used homology models of the sweet taste receptors, molecular docking of sweet ligands to the receptors, and site-directed mutagenesis of the receptors to identify potential ligand binding sites of the sweet taste receptor. These studies have led to a better understanding of the structure and function of this heterodimeric receptor, and can act as a guide for rational structure-based design of novel non-caloric sweeteners, which can be used in the fighting against obesity and diabetes.

18 December 2019 in Psychopharmacology
Verified
Journal Article
Open access
PDF file
NFNeiloufar Family
Neiloufar Family
EMemeline maillet
emeline maillet
LWLuke T. J. Williams
Luke T. J. Williams
EKErwin Krediet
Erwin Krediet
RCRobin L. Carhart-Harris
Robin L. Carhart-Harris
SRShlomi Raz
Shlomi Raz
Research has shown that psychedelics, such as lysergic acid diethylamide (LSD), have profound anti-inflammatory properties mediated by 5-HT2A receptor signaling, supporting their evaluation as a therapeutic for neuroinflammation associated with neurodegenerative disease. Objective: This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally repeated administration of 5 μg, 10 μg, and 20 μg LSD in older healthy individuals. In the current paper, we present safety, tolerability, pharmacokinetics, and pharmacodynamic measures that relate to safety, tolerability, and dose response. Methods: This was a phase 1 double-blind, placebo-controlled, randomized study. Volunteers were randomly assigned to 1 of 4 dose groups (5 μg, 10 μg, 20 μg LSD, and placebo), and received their assigned dose on six occasions (i.e., every 4 days). Results: Forty-eight older healthy volunteers (mean age = 62.9 years) received placebo (n = 12), 5 μg (n = 12), 10 μg (n = 12), or 20 μg (n = 12) LSD. LSD plasma levels were undetectable for the 5 μg group and peak blood plasma levels for the 10 μg and 20 μg groups occurred at 30 min. LSD was well tolerated, and the frequency of adverse events was no higher than for placebo. Assessments of cognition, balance, and proprioception revealed no impairment. Conclusions: Our results suggest safety and tolerability of orally administered 5 μg, 10 μg, and 20 μg LSD every fourth day over a 21-day period and support further clinical development of LSD for the treatment and prevention of Alzheimer’s disease (AD).

1 May 2010 in Journal of Molecular Biology
Verified
Journal Article
Closed access
FAFariba Assadi-Porter
Fariba Assadi-Porter
EMemeline maillet
emeline maillet
JRJames T. Radek
James T. Radek
JQJeniffer Quijada
Jeniffer Quijada
JMJohn L. Markley
John L. Markley
MMMarianna Max
Marianna Max

15 September 2015 in Chemical Senses
Verified
Journal Article
Open access
PDF file
EMemeline maillet
emeline maillet
MCMeng Cui
Meng Cui
PJPeihua Jiang
Peihua Jiang
MMMihaly Mezei
Mihaly Mezei
EHElizabeth Hecht
Elizabeth Hecht
MMMarianna Max
Marianna Max
The sweet taste receptor, a heterodimeric G protein-coupled receptor comprised of T1R2 and T1R3, binds sugars, small molecule sweeteners, and sweet proteins to multiple binding sites. The dipeptide sweetener, aspartame binds in the Venus Flytrap Module (VFTM) of T1R2. We developed homology models of the open and closed forms of human T1R2 and human T1R3 VFTMs and their dimers and then docked aspartame into the closed form of T1R2’s VFTM. To test and refine the predictions of our model, we mutated various T1R2 VFTM residues, assayed activity of the mutants and identified 11 critical residues (S40, Y103, D142, S144, S165, S168, Y215, D278, E302, D307, and R383) in and proximal to the binding pocket of the sweet taste receptor that are important for ligand recognition and activity of aspartame. Furthermore, we propose that binding is dependent on 2 water molecules situated in the ligand pocket that bridge 2 carbonyl groups of aspartame to residues D142 and L279. These results shed light on the activation mechanism and how signal transmission arising from the extracellular domain of the T1R2 monomer of the sweet receptor leads to the perception of sweet taste.